SENXUAN(830946) Jianghai Securities·2025-01-22 11:33Investment Rating - The investment rating for the company is "Hold (First Coverage)" [1] Core Views - The company focuses on the production of active pharmaceutical ingredients (APIs) and intermediates, aiming to become a leading domestic and globally recognized manufacturer in this field. It has a clear strategy to diversify into innovative and generic drugs while maintaining a strong position in the API market [4][25][39] - The company has a stable customer base, with the top five customers accounting for 27.27% of sales in 2023, indicating strong customer relationships and stable sales channels [40][44] - The company has faced financial pressures in recent years, with a decline in revenue and net profit, but the decline in net profit has narrowed as of Q3 2024, showing signs of stabilization [7][43] Summary by Sections Company Overview - Jiangsu Senxuan Pharmaceutical Co., Ltd. was established in 2003 and is one of the first companies listed on the Beijing Stock Exchange. The company has a clear ownership structure with state-owned assets controlling 72.31% of shares, providing strategic guidance and support for sustainable development [11][22] - The company has received various recognitions, including "Specialized, Refined, Characteristic, and Innovative" and "High-tech Enterprise" certifications, which enhance its market competitiveness [17] Financial Forecast - The company's total revenue is projected to be 533.55 million yuan in 2024, with a growth rate of -9.50%, followed by 622.44 million yuan in 2025 and 718.17 million yuan in 2026, with growth rates of 16.66% and 15.38% respectively [5] - The net profit attributable to shareholders is expected to be 123.23 million yuan in 2024, with a decline of 8.39%, followed by 135.39 million yuan in 2025 and 159.25 million yuan in 2026, with growth rates of 9.87% and 17.62% respectively [5] Industry Development - The global pharmaceutical industry is experiencing continuous growth, driven by population growth and aging trends, which presents opportunities for companies in this sector [2][16] - The company is positioned to benefit from the expiration of patents for original drugs and the acceleration of domestic approvals, allowing it to deepen its product development and optimize its product structure [29][30] Valuation and Investment Recommendations - The current market valuation corresponds to a price-to-earnings (P/E) ratio of 32.53 for 2024, 29.61 for 2025, and 25.17 for 2026, indicating a favorable outlook for future earnings growth [5][7]